CTLA4 and glioblastoma: Meanwhile, an ongoing phase I study is evaluating the safety and efficacy of IL-13Rα2–CAR-T therapy together with nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4), underscoring the interest in this multi-modal strategy for GBM [142,143].